New Hope for Customized T Cell Therapy for Cancer
T cells play a crucial role in the identification of T cell receptor (TCR).
Now, researchers can genetically modify T cells to specifically recognize tumor markers. To this end, they construct a virus construction that encodes specific a tumor antibody to "infect" T cells. The resulting T cells express chimeric antigen receptors (CAR) on their surfaces, which enable them to identify and kill tumor cells. This tool has a strong effect on some cancers, but their effectiveness remains to be confirmed.
In a broad sense, there are two major types of cancer: blood (or liquid) cancers from blood cell and solid tumors from any other tissue in the body. Over the past ten years, CAR T cells have become one of the most promising approaches for the treatment of cancer. Now, new research suggests that these treatments may be able to combat B cell cancer, and also be effective in the treatment of solid tumors.
Recently, researchers have found that CAR T cells specific to CD19 can mediate tumor regression derived from B cell, such as acute lymphoblastic leukemia (ALL). But CD19 may be the perfect target, and ALL may be the perfect disease. The use of this approach against other tumors get a frustrating result.
The difficulty in targeting solid tumors is to find the suitable CAR T cell target. This objective is present in glioblastoma, which is the most common and most aggressive brain tumor.
At present, although there is a lot of progress in the laboratory and clinical. In some patients, CAR T cell cytotoxicity is showed. For most people, there is no danger, but it may be a safety problem. At the same time, the production of T CAR cells is also very expensive, labor intensive and time consuming. Patients need to participate in the trial. Their T cells must be separated, redesigned, and validated before re-injected and tested. We need to find out how to make the production process more simple, faster, more importantly and cheaper, so that you can have more business feasibility.